Quarterly report pursuant to Section 13 or 15(d)

Other current assets

v3.19.3
Other current assets
 9 Months Ended
Sep. 30, 2019
Other current assets  
Other current assets

Note 10 — Other current assets

Other current assets consisted of the following (in thousands):

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31, 

​

    

2019

    

2018

Corporate tax receivable

 

$

30,341

 

$

16,459

Prepayments

 

​

10,391

 

​

6,279

Clinical materials

 

​

1,522

 

​

1,087

VAT receivable

​

​

1,385

​

​

1,505

Other current assets

 

​

471

 

​

439

​

​

$

44,110

​

$

25,769

​

In October 2019, the Company received $15.8 million of the above Corporate tax receivable balance, which related to qualifying research and development expenditure in 2018. The remainder of the corporate tax receivable balance above relates to 2019.